Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
US Department of Justice
Teva
Farmers Insurance
Colorcon
Fuji
Mallinckrodt
Cerilliant
Queensland Health

Generated: November 18, 2018

DrugPatentWatch Database Preview

Encorafenib - Generic Drug Details

« Back to Dashboard

What are the generic sources for encorafenib and what is the scope of encorafenib freedom to operate?

Encorafenib is the generic ingredient in one branded drug marketed by Array Biopharma Inc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for encorafenib
US Patents:11
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 30
Clinical Trials: 7
Patent Applications: 61
DailyMed Link:encorafenib at DailyMed
Synonyms for encorafenib
1269440-17-6
8L7891MRB6
AC-30230
AKOS027254498
AS-35201
BDBM221688
Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester
CHEMBL3301612
CMJCXYNUCSMDBY-ZDUSSCGKSA-N
CS-2289
D0TK7R
D11053
DB11718
DTXSID00155347
Encorafenib (JAN/USAN/INN)
Encorafenib (LGX818)
Encorafenib [USAN:INN]
EX-A1587
GTPL7908
HY-15605
KB-145917
LGX 818
LGX-818
LGX-818(Encorafenib)
LGX818
Methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate
methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
MolPort-035-395-871
NVP-LGX818
NVP-LGX818-NXA
s7108
SCHEMBL8228295
UNII-8L7891MRB6
US9314464, 9
ZINC68249103

US Patents and Regulatory Information for encorafenib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
US Department of Justice
Teva
Farmers Insurance
Colorcon
Fuji
Mallinckrodt
Cerilliant
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.